Lianhe Aigen Pharmatech Co., Ltd. is a wholly-owned subsidiary of Lianhe Aigen Pharma Co., Ltd. (formerly known as Lianhe Chemical Technology (Taizhou) Co., Ltd.). Lianhe Aigen is committed to providing one-stop CRDMO services including new drug discovery, preclinical, clinical and commercial stages for the world's leading innovative pharmaceutical companies, empowering global innovative drugs and contributing to human health.

Our facilities are successfully inspected by FDA, EMA, PMDA, TGA, KFDA and NMPA.

Our Services

Drug Discovery:

• Scaffold design for hit identification
• Library synthesis
• Generation and optimization of hit compounds
• Identification and optimization of lead compounds
• Scaling-up synthesis and process optimization of preclinical candidate compounds
• Patent filing support

Process Development:

• Process development and optimization
• Analytical method development and optimization
• Integrated CMC service
• Process safety evaluation, DSC, RC1, ARC, etc.
• Development and optimization of recrystallization process
• Treatment of highly potent compounds
• Process validation and transfer
• Registration support

Contract Manufacturing:

• Provide process scaling up services
• Commercial Production
• Capable of delivering products from lab level to kg level to tonnage level
• Provide process validation services
• Multiple GMP & non-GMP multi-purpose workshops at difference sizes
• Customized specialized commercial workshop according to customer’s project requirements

CMC Service:

• Synthetic route scouting and optimization
• Impurity characterization and control strategy
• Quality control strategy
• Method development and validation
• Critical process parameter identification and process validation 
• Stability studies
• Global regulatory submission
• Pre-clinical and commercial material supply
• Transportation validation